Manager TitleAgeSince
Corporate Secretary 60 2019-08-07
Director TitleAgeSince
Director/Board Member 60 2019-06-06
Director/Board Member 49 2020-04-20
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-0.81%-0.33%+27.15%+81.12% 55.23B
+2.84%-4.80%+28.84%+67.57% 53.75B
-0.11%+0.86%-15.63%-13.56% 23.48B
-1.58%-5.51%-3.51%+375.36% 22B
+2.59%-0.92%+20.31%-12.15% 19.78B
+0.27%-1.38%+28.87%-33.53% 17.44B
+0.83%-5.95%+16.20%+539.84% 14.66B
+1.16%+0.58%+51.87%+181.96% 14.07B
-5.09%-10.87%+153.11%+272.20% 13.02B
Average -0.05%-1.55%+34.13%+162.09% 25.94B
Weighted average by Cap. +0.30%-0.44%+27.72%+125.28%
Logo Nightstar Therapeutics PLC
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company's lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company's third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Employees
-